Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache SocietyAn extension phase of the DELIVER study with Vyepti® (eptinezumab) demonstrated long-lasting migraine preventive effects with treatment for up to 18 months, reducing both frequency and severity.
First-time presentation of a real-world evidence study that revealed high overall satisfaction with the effectiveness of VYEPTI treatment for chronic migraine among most patients and their treating neurologists, as well as positive infusion experienceHarris Poll Migraine Report Card Survey uncovers racial and ethnic.
Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data at the 65th Annual Scientific Meeting of the American Headache Society, Reinforcing Its Use in Migraine Prevention wsiltv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsiltv.com Daily Mail and Mail on Sunday newspapers.